As the 2026 FIFA World Cup kicks off in Mexico this Thursday, we take a look at the tournament’s expected economic impact – both globally and on host countries. But the real winner, it seems, is FIFA, ...

AI has taken the world by storm over the last few years, with millions of users writing prompts on platforms like ChatGPT to generate content, images, and yes videos. Still, some of these platforms ...

The NFL Draft is set for April 23-25, but attention is already beginning to shift to 2027 and its quarterback class. Five signal-callers are emerging as early names to watch, with some analysts ...

In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, deeply weird. Credit...Illustration by Pablo Delcan and Danielle Del Plato ...

Andrea Pavan has been released from the hospital, one week after he was seriously injured in a freak elevator accident. Pavan, 36, was forced to withdraw from last week’s South African Open in ...

One week after he was involved in a terrible elevator accident in South Africa, Italian pro golfer Andrea Pavan was released from a hospital on Wednesday. In an Instagram post that included a picture ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

A two-time DP World Tour winner suffered a serious—and freak—off-course injury ahead of this week's Investec South African Open. According to Monday Q Info's Ryan French, Andrea Pavan was badly ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines' anti-TSLP antibody GB-0895 is currently being evaluated in a pair of phase 3 studies for severe asthma. (Stock photo/Getty Images) Clinical-stage antibody company ...